Search

Author/Creator Dekkers, Claire C J

1. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Issue 7 (July 2020)

Authors:
Cherney, David Z I; Dekkers, Claire C J; Barbour, Sean J; Cattran, Daniel; Abdul Gafor, Abdul Halim; Greasley, Peter J; Laverman, Gozewijn D; Lim, Soo Kun; Di Tanna, Gian Luca; Reich, Heather N; Vervloet, Marc G; Wong, Muh Geot; Gansevoort, Ron T; Heerspink, Hiddo J L
Journal:
Lancet
Issue:
Volume 8:Issue 7(2020)
Page Start:
582
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. Issue 7 (11th May 2018)

Authors:
Dekkers, Claire C J; Wheeler, David C; Sjöström, C David; Stefansson, Bergur V; Cain, Valerie; Heerspink, Hiddo J L
Journal:
Nephrology dialysis transplantation
Issue:
Volume 33:Issue 7(2018)
Page Start:
1280
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗